Identifying Influencing Factors in the Decision-Making Process for Bladder Cancer PatientsIdentifying Influencing Factors in the Decision-Making Process for Bladder Cancer PatientsThe study involves gathering information via one-on-one patient interviews, surveys and questionnaires so that we can better understand the patient decision-making process involved in bladder cancer treatment. ClinicalTrials.gov registration not required
Robert Svatek MDA Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.NCT06479135
Zohra Nooruddin MD
Clinical Trial
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP-binding site TKI with discontinuation due to treatment failure, warning, or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.
APOBEC3 Expression in HPV-Related Malignancies as a Novel Biomarker of Response to Definitive ChemoradiationAPOBEC3 Expression in HPV-Related Malignancies as a Novel Biomarker of Response to Definitive ChemoradiationThis is a non-randomized biomarker study with the aim to evaluate the relationship between APOBEC3B (A3B) expression in primary head and neck cancers (HNC), anus, and cervix tumors and pathologic response to definitive chemoradiation therapy.ClinicalTrials.gov registration not required
Shraddha Dalwadi, MD, MBANRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)This phase III trial compares the effect of adding radiation therapy to usual care on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causing symptoms (asymptomatic). High-risk bone metastases are defined by their location (including hip, shoulder, long bones, and certain levels of the spine), or size (2 cm or larger).ClinicalTrials.gov registration not required
Shraddha Dalwadi, MD, MBAShortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-Center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men with Node-Positive and High-Risk Node-Negative InvShortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-Center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men with Node-Positive and High-Risk Node-Negative InvTo learn about the effects of shorter RNI regimens in patients with breast cancer who have had a lumpectomy or mastectomy and who are at higher risk for lower risk for the disease returning.NCT07076485
Shraddha Dalwadi, MD, MBA
Close
